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Abstract
Objective. This investigation aims to review the known genetic
mutations associated with oral cavity squamous cell carcinoma
(OCSCC) in young adults with limited environmental risk factors (YLERs).
Data Sources. A comprehensive search strategy was designed
to identify studies in MEDLINE (Ovid), Embase (Ovid), and
Scopus from database inception to May 2017 that included
adults 50 years of age with OCSCC and minimal tobacco
use history (10 pack-years) who had their tumors genetically sequenced or mutational profiles analyzed.
Review Methods. Identified articles were screened by 2
reviewers. Quality of evidence was graded by the MINORS
criteria for case-control studies; other studies were graded
by assigning a level of evidence for gene mutation literature.
Results. Thirteen studies met our inclusion criteria, and 130
patients met our criteria for age and tobacco history. TP53
was the most commonly evaluated gene (10 of 13 studies)
and the most frequently observed mutation. One study
reported that nonsmokers had significantly fewer TP53
mutations, while 9 studies found no difference in the prevalence of TP53 mutations. No other mutations were found
specific to this cohort.
Conclusions. TP53 mutations may occur at a similar rate in
YLERs with OCSCC as compared with older patients or those
with risk factors. However, few studies have aimed to characterize the genetic landscape of oral cavity tumors in this population, often with small sample sizes. Future studies are needed
to explore unidentified genetic alterations leading to tumor susceptibility or alternative mechanisms of carcinogenesis.
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T

raditionally, oral cavity squamous cell carcinoma
(OCSCC) has been observed in older men with a history of environmental risk factors, such as tobacco
and alcohol use. While the incidence of oropharyngeal
cancer has been increasing due to carcinogenic strains of
human papillomavirus (HPV), the overall incidence of squamous cell carcinoma seen in the oral cavity has
decreased.1,2 It is hypothesized that this is due to the declining rates of tobacco use in younger patient populations.3
While the overall incidence of OCSCC is decreasing, the
frequency of oral tongue squamous cell carcinoma
(OTSCC) has been observed to be increasing, particularly in
this younger cohort of patients.4,5 Specifically, a higher rate
has been reported among young White individuals (\50
years) without traditional risk factors and predominantly
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among women.6-8 Tobacco use in this young cohort with
oral tongue cancer has been reported to range between 10%
and 50%.7,9 Furthermore, this increase in OTSCC has been
observed among the same birth cohorts in White men and
women, particularly those born after the 1940s.10 Strikingly,
this same increase in incidence has not been observed
among other subsites of the oral cavity, such as the buccal
mucosa, upper and lower alveolus and gingiva, hard palate,
or floor of mouth.11
To date, there has been no definitive etiology proposed
for the increasing incidence of OTSCC, despite the suggestion that a combination of genetic predisposition and environmental exposures may portend an elevated risk.12 As the
application of next-generation sequencing technologies continue to rapidly develop, identifying genetic mutations present in this young OCSCC population with low environmental
risk may provide insight into causality and/or potential targeted therapies. This article aims to review the known mutational landscape of OCSCC, particularly of the oral tongue
subsite, in young adults with low environmental risk (YLERs).
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The articles describing gene mutations discovered
through our search strategy were reviewed and assigned a
level of evidence for gene mutation literature, as adapted to
our study from a previous study of genetic mutations in pulmonary artery hypertension.14 Case-control studies were
graded according to the MINORS criteria (Methodological
Index for Non-randomized Studies; Table 1).15

Results
Literature Overview and Study Selection
Our search yielded a total of 187 records across all databases. After deduplication, 181 unique records remained.
The PRISMA flow diagram in Figure 1 summarizes the
results of the study selection process. Thirteen articles met
the inclusion criteria: 8 case series, 3 case-control studies,
and 2 case reports.

Risk-of-Bias Assessment

This systematic review was conducted in accordance with
the recommendations of the PRISMA statement (Preferred
Reporting Items for Systematic Reviews and Metaanalyses).13

Ten studies showed negative evidence for increased TP53
gene mutations in YLERs with OCSCC; 1 showed experimental evidence for other genetic alterations in YLERs with
OCSCC; and 2 had genetic evidence in OCSCC-related disease. The MINORS criteria scores for the 3 case-control
studies16-18 ranged from 3 to 5 (out of 7). The levels of evidence and MINORS criteria scores are listed in Table 1.

Search Strategy

Patterns of TP53 Mutation and Expression

A comprehensive search strategy was designed and executed
by R.P. in MEDLINE (Ovid), Embase (Ovid), and Scopus
for results published from database inception through May
17, 2017. The search strategy utilized all relevant controlled
vocabulary and keyword terms in an effort to yield all
results with data pertaining to the mutational landscape of
OCSCC in adults with a tobacco use history 10 packyears.

TP53 was the most commonly evaluated gene, analyzed in
10 of the 13 studies. Nine studies revealed no difference in
TP53 mutation rates between YLERs and their counterparts
with OCSCC, though the types of mutations and expression
rates varied.16,17,19-25 Two studies revealed that YLERs did
not have mutations in exons 5 to 9 of TP53, whereas older
smokers had mutations in this region.17,23 However, 2 studies identified mutations within this region of TP53. Vettore
et al found no mutations unique to younger patients or nonsmokers and that the types of base changes were similar
between cohorts.25 Tan et al identified no significant correlation regarding mutational status in genes tested in a panel
for lung cancer, which included TP53 and smoking history,
with the caveat that a low number of YLERs (n = 2) were
included in their cohort.24 Krishnan et al reported that TP53
mutations were similar among YLERs and their counterparts, but they reported a 20% lower TP53 mutational frequency (somatic mutation frequency per megabase) in the
nonsmoking group across all ages.20 However, Pickering et
al and Braakhuis et al noted that TP53 was more typically
inactivated in younger patients, though this was not statistically significant.16,21 When comparing expression of p53
with mutations in TP53, 1 study noted that 81% of YLERs
with OCSCC overexpressed p53 by immunohistochemistry
and that the pattern of overexpression was highly correlated
with the histologic grade of the tumor, despite not finding
any TP53 mutations in the targeted region, exons 5 to 9,
where 92% of TP53 mutations typically occur.22,26 This
reported rate of p53 overexpression was slightly higher than

Methods

Eligibility Criteria and Study Selection
Studies in the English literature were included that pertained
to adults 50 years old (‘‘young’’) who had OCSCC, a
smoking history 10 pack-years (‘‘nonsmoking’’), and their
tumors genetically sequenced or mutational profiles analyzed. Ten pack-years was chosen as the cutoff for smoking
history due to a previous analysis showing significant escalation in the risk of OCSCC development above this amount
for adults of all ages.4 Studies without information pertaining to genetic mutations were excluded. While OTSCC was
the primary focus of our review, given the low number of
relevant studies, all oral cavity subsites were included in the
eligibility criteria to capture the maximum number of cases.
For the same reason, records of alcohol and smokeless
tobacco habits were not factored into the eligibility criteria.
Study selection was conducted independently by 2 reviews
(K.O.S. and R.R.B.) in 2 successive rounds. Records that
appeared to meet eligibility criteria or could not be definitively excluded were advanced to the second round, wherein
they were screened on the basis of full text.
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Study

a

Case series

Case series

Case series

Case Series

Case-control

Case series

Case series

Case series

Case-control

Case-control

Case report

Case series

Type

PCR-SSCP, direct sequencing:
TP53 (exons 4-9)
IHC: p53 protein. PCR-SSCP,
direct sequencing: TP53 (exons
4-10)
Sequenom multiplexed
LungCarta panel 1.0
HuSNP assay. Microsatellite
analysis: chromosome 3p, 6q,
9. HPV: qPCR of E6/E7 regions
of HPV16. FANC-C gene
sequencing: IVSF-41 locus
WES and targeted deep
sequencing

WES. CNA

IHC: p53 protein. PCR-SSCP,
direct sequencing: TP53 (exons
5-9)
WES. CNA. HPV: type specific.
qPCR or HPV16 digital PCR

WES. Oncogenic viruses: RNA
massively parallel sequencing

Sanger sequencing: TP53 (exons
5-9). HPV: p16-IHC followed
by HPV-DNA GP51/61 PCR

NA

IHC: p53 and Bcl-2 proteins.
PCR-SSCP: TP53 (exons 5-9)

Methods used

Table 1. Summary of the Included Articles and Mutations.

\1 y

No reported history

No reported history

No reported
smoking history

No reported use

\1 pack-year

Not explicitly
defined

No reported direct
exposure

No history of
tobacco smoking

No lifetime smoking
history or quit 5
y previously
No reported
smoking history
10 pack-year
smoking history

NS criteria

\1 y

NA

NA

NA

No reported use

Not provided

Not explicitly
defined

No reported direct
exposure

No history of
tobacco chewing

NA

NA

NA

Smokeless
tobacco use

NA

No reported history

NA

No reported alcohol use

Not included

Not provided

Not explicitly defined

3 drinks/wk

None provided

11 patients had .
10 unit-years

Never used

All were ‘‘moderate /
social’’ consumers

Alcohol use

18

16

2

6

2

16

20

21

6

19

1

8

No. meeting
criteria

Oral tongue

Oral tongue, front
of mouth,
mandible

Oral tongue

Alveolus, oral
tongue
Oral tongue

Oral tongue

Oral tongue

Oral tongue

Oral tongue,
retromolar
trigone, cheek,
floor of mouth
Oral tongue

Cheek

Oral tongue

OCSCC
locations

Singapore

USA

Singapore

USA

India

USA

India

USA

USA

Netherlands

Austria

Finland

Study
location

(continued)

TP53, DST, USH2A,
PRKDC, LRP1B,
MACF1, RNF213,
MLL3/KMT2C,
COL6A6,
PKHD1L1, VWA8,
PLEC, SYNE1, BAI3,
FN1, ZFHX4,
PKHD1, KIAA1731,

AI: 3p, 6q, 9p, 9q.
No YLERs had
mutations in IVSF41

STK-11, BRAF

No YLERs had TP53
mutations

TP53, CDKN2A,
CASP-8, NOTCH1,
DMD, U2AF1,
OBSCN
TP53, FAT1,
CDKN2A, CASP8,
NOTCH1, MLL2,
PIK3CA
TP53

TP53, CTNNA3,
EIF3A, EP300,
FXR1, NEK8,
NOTCH1,
NOTCH2,
NOTCH3, PIK3CA,
PKHD1L1,
PTCHD2, RALGAPB,
SPEN, UBR4
No YLERs had TP53
mutations

TP53

AIRE

TP53

Mutations
in YLERs

vii
Vinarsky (2009)30

Abbreviations: AI, allelic imbalance; CNA, copy number alteration; IHC, immunohistochemistry; LOE, level of evidence; MINORS, Methodological Index for Nonrandomized Studies; NA, not available; NS, nonsmoking; OCSCC, oral cavity squamous cell carcinoma; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; SSCP, single-strand conformation polymorphism; WES, whole-exome
sequencing; YLER, young adults with low environmental risk.
a
The levels included (i) annotation error, (ii) unrelated, (iii) negative evidence, (iv) related but not mutated, (v) mutation evidence in OCSCC, (vi) other genetic alterations in OCSCC, and (vii) genetic evidence
in OCSCC-related disease.
b
MINORS: 3 out of 7.
c
MINORS: 5 out of 7.

USA
Oral tongue
1
No reported history
NA
\2 pack-years
CDKN2A sequencing:
INK4a locus
Case report

Study
location
OCSCC
locations
No. meeting
criteria
Alcohol use
Smokeless
tobacco use
NS criteria
Methods used
Study

Table 1. (continued)

LOE

a

Type

APC, DLEC1,
LILRB1, SYNE2,
FAT1, FAT2, FAT3,
FAT4, PDE4DIP,
RYR2, DNHD1,
CASP8, ZSWIM5,
COL27A1
INK4a
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Mutations
in YLERs
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previously reported rates in ‘‘classical’’ squamous cell carcinoma of the head and neck, in contrast to previous studies
showing a strong correlation between p53 overexpression
and tobacco and alcohol usage.22,27,28
One study revealed that nonsmokers had significantly
fewer TP53 mutations when compared with smokers. Li
et al performed exomic sequencing on samples from 6
never-smokers with OTSCC and compared them with 5
smokers elected as controls.18 We were able to obtain
demographic data on the 6 never-smokers: 5 of the 6 were
50 years old, 1 of whom had a TP53 mutation. In contrast,
all 5 sequenced smokers had TP53 mutations. Never-smokers had significantly fewer TP53 mutations than smokers.

Other Mutational Differences
Other mutations unique to the population of YLERs were
CDKN2A, RASA1, STK-11, and BRAF, though none were
specific for this population.20,24 The 2 case reports identified INK4a and AIRE as mutated genes in YLERs with
coexisting conditions who developed OCSCC.29,30 Other
genetic perturbances were found by Tong et al, who discovered an elevated frequency of allelic loss in a novel region
on chromosome 6q, though there was otherwise no difference between young nonsmokers and their counterparts.31
Chromosome 9q had a high rate of loss of heterozygosity
(LOH) and allelic imbalance. The authors found no evidence of HPV-16 infection or FANC-C IVSF-41 mutations
in any of the nonsmoker samples. Li et al reported distinct
mutational spectrums between the cohorts, with a greater
proportion of C:G.G:C transversions in cancers from nonsmokers (P \ .0001) and A:T.G:C (P \ .0001) or
A:T.T:A substitutions (P \ .0001) among smokers.18
Three studies tested for presence of HPV; however, none of
the samples from nonsmoking patients contained evidence
of HPV.

Discussion
While traditional environmental risk considerations regarding the development of OTSCC have largely implicated
tobacco use, OTSCC in young nonsmokers is becoming
increasingly prevalent despite declining smoking rates
worldwide.5 Interestingly, the rate is decreasing among nonWhites and non-Hispanics, as well as in those .45 years of
age across all ethnicities.6 Though OTSCC in YLERs has
emerged as a distinct clinical entity, studies to date have
failed to identify a clear etiology. Our review attempts to
synthesize our existing knowledge of the genetic changes
underlying carcinogenesis in this unique cohort.

TP53 Mutations
The rate of TP53 mutations is overall similar between
YLERs with OTSCC and older smoking patients with
OTSCC. Our findings do differ somewhat from prior studies
indicating that TP53 mutations may be less predominant
among nonsmokers with head and neck squamous cell carcinoma (HNSCC).32,33 Of 10 studies evaluating TP53 mutations in this population, only 1 reported significantly fewer
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Records idenﬁed through
database searching
(n = 181)

Addional records idenﬁed
through other sources
(n = 0)

Included

Eligibility

Screening

Records aer duplicates removeda
(n = 178)

Records screened
(n = 178)

Records excluded
(n = 127)

Full-text arcles assessed
for eligibility
(n = 51)

Full-text arcles excluded,
with reasons
(n = 38)
Wrong paent
populaon (n = 25)
Wrong study design
(n= 4)
Duplicate study/data
(n= 3)
Full text unavailable (n
= 6)

Studies included in
qualitave synthesis
(n = 13)

Figure 1. PRISMA flow diagram illustrating the selection process of the included articles.

TP53 mutations among never-smokers.18 Some of these differences may be attributable to small sample sizes and variations in sequencing methods, which limits the ability to
form definitive conclusions regarding mutational differences. However, it is also possible that the TP53 mutations
found in this cohort differ from those typically seen in other
HNSCCs. For instance, several studies suggest that TP53
mutations in this population may be occurring in locations
other than those traditionally seen in HNSCC. Although it
was previously shown that almost all TP53 mutations seen
in HNSCC occur within exons 5 to 9, multiple studies
included in our review found mutations either to be absent
or outside this region.17,22,23 As a number of studies
sequenced limited high-yield exons or focused on previously
determined hotspot mutations, more widely distributed inactivating mutations or those in other exons may have gone
undetected.17,23,24 In fact, Singh and colleagues found that
exon 4 was the most commonly mutated exon, and they
identified several novel TP53 mutations, many occurring
outside predetermined ‘‘hot spots.’’17 Furthermore, the type
of TP53 mutation, rather than the frequency or location,
may play a role. One study reported a higher rate of
truncating-type TP53 mutations in younger patients.16
Truncating mutations have been associated with poorer
prognoses in HNSCC,34 which may explain why some studies suggest poorer outcomes in YLERs with OTSCC.
Moreover, there appears to be no predictable relationship

between TP53 and p53 protein expression, as reflected in
many of the included studies.19,22,23
Truncation events may lead to lack of expression or
inability to detect the truncated protein through available
methods, thus making it challenging to define the affiliation
between mutation and expression. Importantly, these mutational differences may have implications in terms of prognosis and effectiveness of potential therapies in this
population. Overall, it appears that TP53 mutations are present at similar rates in YLERs with OTSCC, though clinical
history and associated mutational spectra suggest an underlying mechanism unrelated to direct carcinogen exposure
that has yet to be ascertained.

Other Potentially Implicated Genes
The pathogenesis of OTSCC in YLERs is likely to be multifactorial, and TP53 is seemingly one of the few implicated
genetic drivers in this population. Though no other gene
mutations were found to be specific to this patient population, several genes were differentially mutated according to
age and risk factors. One study found the CDKN2A gene,
previously noted to be present in OCSCC, to be mutated
exclusively in nonsmokers and past-smokers.20,35 It also
noted a higher rate of mutations in the arachidonic acid and
Toll-like receptor pathways in the nonsmoking population.20
RASA1 may play a role in a subpopulation of patients based
on exposure, as it was found to be specific to patients who
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had never chewed tobacco, regardless of smoking history.20
The roles of other commonly altered genes—such as CASP8, NOTCH-1, FAT1, and PIK3CA, which were found to be
less frequently mutated in YLERs—remain in question but
may be involved in the regulation of key signaling pathways
involved in tumorigenesis.32 INK4a, often mutated in
FAMMM, may be involved in the development of recurrent
HNSCC, whether as part of a familial cancer syndrome or
as an isolated genetic marker for the development of
HNSCC in young adults.30,36 Other coexisting genetic conditions, such as Fanconi anemia, may have some significance, but this role remains to be clearly defined. Overall,
our review did not identify HPV to be associated with
malignancy in this group of patients, which follows the general consensus suggesting that HPV does not play a major
role in the development of OCSCC/OTSCC in this young
population.37-39

Differing Mutational Landscapes and Genetic Contexts
The genome-wide mutational landscape may be different in
YLERs with OCSCC. For instance, one study in our review
found elevated rates of allelic imbalance in chromosomes
6q and 9q in nonsmokers.31 A study not included in our
review found increased rates of LOH in distal regions of
chromosome 17p, home to TP53, and other loci in
YLERs,40 which have been linked to driving the transition
from hyperplasia to dysplasia in HNSCC.32,40 While it
found the degree of LOH at chromosomes 3, 9, and 17p to
be similar among younger and older patients with OCSCC,
the evaluation of additional chromosomes may reveal yet
unknown molecular characteristics in this population.40 Of
note, a prior study evaluating lung cancer identified a
region on chromosome 6q that conferred an increased risk
of cancer in never-smokers and light smokers (with ‘‘light’’
defined as \20 pack-years) who had a particular ‘‘risk haplotype.’’41 Although the reviewed study identified regions
of loss without distinct haplotypes,31 further investigation in
this and other areas of the genome may provide insight into
potential susceptibility loci.
It should be noted that race and sex may affect the
genetic changes underlying tumorigenesis in particular
populations, and it has been demonstrated that certain genes
are differentially mutated in OTSCC across ethnicities. For
instance, Asian patients with OTSCC were found to have
mutations in genes such as DST, RNF213, STK-11, and
BRAF, whereas the largely North American cohort represented in The Cancer Genome Atlas had more frequent
mutations in TP53, CDKN2A, and NOTCH1.24,25 These biologic differences should not be overlooked as potential contributing factors, and further investigation into this aspect of
OTSCC may provide important information regarding
underlying etiology and perhaps even prognosis.
Finally, while OTSCC in YLERs exists as a distinct clinical and epidemiologic entity, studies to date have yet to
identify any genomic or etiologic factors unique to this subpopulation. Furthermore, often contrasting observations
related to TP53 and other potential genetic drivers are
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difficult to synthesize in light of the limitations accompanying such studies. Additional factors, such as the oral microbiome and immune microenvironment, have been suggested
to play a role in the pathogenesis of OTSCC in YLERs.
Similar to the role of the gut microbiome in gastrointestinal
cancers, the disruption of the normal and potentially ‘‘protective’’ oral microbiome may be associated with the development of OCSCC.42,43 Specifically, there may be a role of
oral candidiasis, as we identified a case report of a patient
with chronic mucocutaneous candidiasis who developed
recurring OCSCC.29 The disruption of the normal oral
microbiome by some Candida species may promote carcinogenesis, possibly through production of carcinogenic factors, and a similar pattern could be the case in YLER
patients with OTSCC.44,45
Emerging research suggests that the primary difference in
OCSCC between smokers and nonsmokers lies in the
immune microenvironment, particularly in the PD-1 and
PDL-1 pathways.46,47 Despite having similar or higher
levels of inflammatory infiltrates as compared with older
smokers, the immune response in YLERs may be attenuated, particularly with regard to immune activation and
immune exhaustion.47 These findings elicit promising
therapeutic considerations, particularly with regard to
immunotherapies, warranting further genetic analysis to
potentially direct future management strategies.

Limitations
Overall, few studies have been conducted on genetic mutations in the young nonsmoking population with OCSCC.
Furthermore, most are restricted by small sample sizes and
are case reports, case studies, or case-control studies, ultimately limiting the applicability of these results. Moreover,
inadequate sample sizes prevent appropriate stratification by
age, sex, and risk habits. Our analysis was also constrained
by discrepancies in the annotation of environmental risk factors. To capture all relevant studies, the use of smokeless
(chewing) tobacco was not included in our selection criteria
due to its inconsistent incorporation among studies.
However, it is an important consideration in this context
given that it may reflect tobacco habits across different
populations and is a known risk factor for the development
of OCSCC. Alcohol use was also not consistently reported,
though it is a well-documented risk factor for the development of OCSCC.48 In addition, the definition of nonsmoking varies considerably among studies, and while all studies
met our criteria of a 10–pack-year history, specific criteria
among individual studies differed. The variations in age and
tobacco criteria used among studies hinder the interpretation
of individual findings and limit our ability to aggregate
data. Last, comprehensive mutational analysis requires significant resources, which often limits the scope of such studies. Significant variation in the methods used to perform
mutational analysis complicates the comparison of findings
among studies. The relative rarity of OTSCC in our targeted
cohort makes it difficult to appropriately power these studies and draw accurate conclusions. While it is apparent that
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further study is needed to gain meaningful insight into this
unique disease process, this review serves as a first step
toward appreciating our existing knowledge base and identifying what remains to be elucidated.
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6.

Conclusions
The rise in OTSCC among young patients without traditional risk factors represents a unique and puzzling clinical
entity. Though a discrete epidemiologic cohort, distinctive
underlying etiologic and genomic factors have yet to be
identified. Our review suggests that TP53 mutations in
YLERs with OTSCC likely occur at a rate similar to that in
the ‘‘traditional’’ cohort of older smokers, and no additional
genetic mutations were found to be specific to this cohort.
Overall, few studies with relatively small sample sizes have
aimed to characterize the genetic landscape of oral cavity
tumors in this growing patient population. Factors such as
the oral microbiome, sex, ethnicity, and various underlying
genetic elements may play unique roles in driving tumor
formation in these patients. Future studies are needed to
explore unidentified tumor susceptibility genes or alternative mechanisms of carcinogenesis in this cohort.
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